Literature DB >> 12739234

Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.

Hongjun Li1, Zhanlong He, Ting Su, Yanbing Ma, Shuaiyao Lu, Changbai Dai, Maosheng Sun.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by muscular trembling palsy due to lack of dopamine (DA) in the substantia nigra-striatum (nigrostriatal) system resulting from the degeneration and necrosis of dopaminergic neurons. No effective cure has been found. Neurturin (NTN) has been demonstrated to act specifically on midbrain (mesencephalic) dopaminergic neurons with protective actions specifically. In the present study, we induced rhesus monkey model of Parkinson's disease by injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Rhesus monkeys were randomly divided into a PD model group, NTN treatment group and normal control groups. In the NTN treatment group, 1 mg of E. coli-derived recombinant human NTN was injected into the cerebral ventricles 48 h before the injection of MPTP. Results indicated that Rhesus monkeys in the PD model group acquired PD symptoms that increasingly aggravated over time, while monkeys treated with NTN had less apparent or no symptoms. Using fluorospectrophotometry, the dopamine (DA), 5, 5-hydroxytrytamine (5-HT) and the 5-hydroxyindoleacetic acid (5-HIAA) contents of DA, 5-HT and 5-HIAA in substantia nigra, putamen and caudate nucleus in monkeys from the model group was found to be significantly lower than in the normal control group. While no significant differences were found between monkeys treated with NTN and normal control groups, the contents of DA, 5-HT and 5-HIAA in the NTN treatment group were higher than those observed in the PD model group. A dramatic loss of neurons in the substantia nigra in monkeys in the PD model group was observed by light microscopy, while no obvious loss was observed in the NTN treatment group in which the numbers of neurons were similar to those in normal controls. These results indicate that recombinant human NTN can prevent PD symptoms as well as protect dopaminergic neurons and preserve DA content in midbrain substantia nigra in rhesus monkeys exposed to MPTP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739234     DOI: 10.1179/016164103101201472

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  9 in total

1.  Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.

Authors:  Adrian P Kells; Jamie Eberling; Xiaomin Su; Philip Pivirotto; John Bringas; Piotr Hadaczek; Wade C Narrow; William J Bowers; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

Review 2.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

3.  Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.

Authors:  Óscar Cordero-Llana; Benjamin C Houghton; Federica Rinaldi; Hannah Taylor; Rafael J Yáñez-Muñoz; James B Uney; Liang-Fong Wong; Maeve A Caldwell
Journal:  Mol Ther       Date:  2014-11-05       Impact factor: 11.454

4.  Electroacupuncture Potentiates Cannabinoid Receptor-Mediated Descending Inhibitory Control in a Mouse Model of Knee Osteoarthritis.

Authors:  Xiao-Cui Yuan; Bing Zhu; Xiang-Hong Jing; Li-Ze Xiong; Cai-Hua Wu; Fang Gao; Hong-Ping Li; Hong-Chun Xiang; He Zhu; Bin Zhou; Wei He; Chuan-You Lin; Hui-Lin Pan; Qiang Wang; Man Li
Journal:  Front Mol Neurosci       Date:  2018-04-06       Impact factor: 5.639

5.  GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson's Disease.

Authors:  Yulia A Sidorova; Mart Saarma; Raimo K Tuominen; Juho-Matti Renko; Merja H Voutilainen; Tanel Visnapuu
Journal:  Front Neurol Neurosci Res       Date:  2020-11-24

6.  Effects of Acupuncture on Behavioral Stereotypies and Brain Dopamine System in Mice as a Model of Tourette Syndrome.

Authors:  Lixue Lin; Lingling Yu; Hongchun Xiang; Xuefei Hu; Xiaocui Yuan; He Zhu; Hongping Li; Hong Zhang; Tengfei Hou; Jie Cao; Shuang Wu; Wen Su; Man Li
Journal:  Front Behav Neurosci       Date:  2019-10-15       Impact factor: 3.558

7.  Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.

Authors:  Arun Kumar Mahato; Jaakko Kopra; Juho-Matti Renko; Tanel Visnapuu; Ilari Korhonen; Nita Pulkkinen; Maxim M Bespalov; Andrii Domanskyi; Eric Ronken; T Petteri Piepponen; Merja H Voutilainen; Raimo K Tuominen; Mati Karelson; Yulia A Sidorova; Mart Saarma
Journal:  Mov Disord       Date:  2019-12-16       Impact factor: 10.338

8.  Potential cellular and regenerative approaches for the treatment of Parkinson's disease.

Authors:  Emma L Lane; Olivia J Handley; Anne E Rosser; Stephen B Dunnett
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

9.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.